Zobrazeno 1 - 10
of 140
pro vyhledávání: ''
Autor:
Ryusaku Matsumoto, Masaaki Yamamoto, Genzo Iguchi, Shin Urai, Hidenori Fukuoka, Wataru Ogawa, Kentaro Suda, Hiroki Shichi, Keitaro Kanie, Yutaka Takahashi, Hironori Bando, Yasunori Fujita
Publikováno v:
Cancer Immunology, Immunotherapy
Background Immune checkpoint inhibitors (ICIs) as a cancer immunotherapy have emerged as a treatment for multiple advanced cancer types. Because of enhanced immune responses, immune-related adverse events (irAEs), including endocrinopathies such as h
Autor:
Mette-Triin Purde, Rebekka Niederer, Nikolaus B. Wagner, Stefan Diem, Fiamma Berner, Omar Hasan Ali, Dorothea Hillmann, Irina Bergamin, Markus Joerger, Martin Risch, Christoph Niederhauser, Tobias L. Lenz, Martin Früh, Lorenz Risch, David Semela, Lukas Flatz
Publikováno v:
Purde, Mette‑Triin; Niederer, Rebekka; Wagner, ikolaus B.; Diem, Stefan; Berner, Fiamma; Hasan Ali, Omar; Hillmann, Dorothea; Bergamin, Irina; Joerger, Markus; Risch, Martin; Niederhauser, Christoph; Lenz, Tobias L.; Früh, Martin; Risch, Lorenz; Semela, David; Flatz, Lukas (2022). Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. Journal of cancer research and clinical oncology, 148(3), pp. 647-656. Springer 10.1007/s00432-021-03870-6
Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Clinical Oncology
Purpose Immune checkpoint inhibitor (ICI)-induced hepatitis belongs to the frequently occurring immune-related adverse events (irAEs), particularly with the combination therapy involving ipilimumab and nivolumab. However, predisposing factors predict
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::812bf92bad1e3210e93f155d71738545
https://boris.unibe.ch/162047/1/Purde2021_Article_PresenceOfAutoantibodiesInSeru.pdf
https://boris.unibe.ch/162047/1/Purde2021_Article_PresenceOfAutoantibodiesInSeru.pdf
Autor:
Yoshikazu Takahashi, Hidekazu Shirota, Takashi Yoshioka, Takuhiro Yamaguchi, Kota Ouchi, Michio Kuroki, Shin Takahashi, Masahiro Takahashi, Masaki Tanaka, Masanobu Takahashi, Chikashi Ishioka, Yasuhiro Sakamoto, Hideki Shimodaira, Hiroo Imai, Satoshi Kato, Keigo Komine, Kazunori Otsuka, Hiroyuki Shibata, Hisatsugu Ohori, Hiroaki Yamaguchi, Yasushi Tsuji
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The current study aimed to determine the efficacy of trifluridine/tipiracil for elderly patients with advanced colorectal cancer. Methods This single-arm, open-label, multicenter, phase II study included elderly patients aged 65 years or more
Autor:
Hamid Abdollahi, Habib Zaidi, Mathieu Hatt, Arman Rahmim, Isaac Shiri, Ghasem Hajianfar, Mehrdad Oveisi, Hasan Maleki, Saeed Ashrafinia
Publikováno v:
Molecular Imaging and Biology, Vol. 22, No 4 (2020) pp. 1132-1148
Shiri, I, Maleki, H, Hajianfar, G, Abdollahi, H, Ashrafinia, S, Hatt, M, Zaidi, H, Oveisi, M & Rahmim, A 2020, ' Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms ', Molecular Imaging and Biology, vol. 22, no. 4, pp. 1132-1148 . https://doi.org/10.1007/s11307-020-01487-8
Molecular Imaging and Biology, 22(4), 1132-1148. SPRINGER
Shiri, I, Maleki, H, Hajianfar, G, Abdollahi, H, Ashrafinia, S, Hatt, M, Zaidi, H, Oveisi, M & Rahmim, A 2020, ' Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms ', Molecular Imaging and Biology, vol. 22, no. 4, pp. 1132-1148 . https://doi.org/10.1007/s11307-020-01487-8
Molecular Imaging and Biology, 22(4), 1132-1148. SPRINGER
Aim: In the present work, we aimed to evaluate a comprehensive radiomics framework that enabled prediction of EGFR and KRAS mutation status in NSCLC cancer patients based on PET and CT multi-modalities radiomic features and machine learning (ML) algo
Autor:
Gemma Castaño-Vinyals, Mercedes Vanaclocha-Espi, Rafael Marcos-Gragera, Vicente Martín, Oscar Zurriaga, Beatriz Pérez-Gómez, Adonina Tardón, María Ederra, Jone M. Altzibar, Carmen Vidal, Ines Gomez-Acebo, Maria Sala, Pilar Amiano, Ana Molina-Barceló, Dolores Salas, Marina Pollán, Marta Hernández-García, Nuria Aragonés, Manolis Kogevinas
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
Cancer Causes Control . 2022 Jan;33(1):125-136
Cancer Causes and Control, 2022, vol. 33, p. 125-136
Articles publicats (IdIBGi)
DUGiDocs – Universitat de Girona
instname
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Cancer Causes & Control
Instituto de Salud Carlos III (ISCIII)
Cancer Causes Control . 2022 Jan;33(1):125-136
Cancer Causes and Control, 2022, vol. 33, p. 125-136
Articles publicats (IdIBGi)
DUGiDocs – Universitat de Girona
instname
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Cancer Causes & Control
This research was supported by Acción Transversal del Cáncer, approved by the Spanish Council of Ministeres on the 11th October 2007, by the Carlos III Health Institute-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286, PS09/01903, PS0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a26453b65c0b79846cf45ef18d8634b
http://hdl.handle.net/20.500.12105/14549
http://hdl.handle.net/20.500.12105/14549
Autor:
M.T. Huizing, Stephen Chan, Stefania Russo, Gail S. Wright, Joyce Steinberg, Andrew M Wardley, Ron Bose, Robyn R. Young, A. Jo Chien, Iulia Cristina Tudor, Andrea Rocca, Lowell L. Hart, Javier Cortes, Kathy D. Miller, Hope S. Rugo, Marie-Pascale Graas, Louise Provencher, Patrick Neven, Jennifer Sugg, Ian E. Krop, David Cameron, Vandana G. Abramson
Publikováno v:
Wardley, A, Cortes, J, Provencher, L, Miller, K, Chien, A J, Rugo, H S, Steinberg, J, Sugg, J, Tudor, I C, Huizing, M, Young, R, Abramson, V, Bose, R, Hart, L, Chan, S, Cameron, D, Wright, G S, Graas, M, Neven, P, Rocca, A, Russo, S & Krop, I E 2021, ' The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer ', Breast cancer research and treatment . https://doi.org/10.1007/s10549-021-06109-7
Breast Cancer Research and Treatment
Scientia
Breast cancer research and treatment
Breast Cancer Research and Treatment
Scientia
Breast cancer research and treatment
Purpose Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor receptor 2-positive (HER2+) breast cancers. In vitro, AR inhibitors enhance antitumor activity of trastuzumab, an anti-HER2 antibody, in trastuzumab-resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98cdcc0d199475dcadec98b642506659
https://lirias.kuleuven.be/handle/20.500.12942/705321
https://lirias.kuleuven.be/handle/20.500.12942/705321
Publikováno v:
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology
Cellular Oncology, Vol 32, Iss 1-2, Pp 57-65 (2010)
Cellular Oncology, Vol 32, Iss 1-2, Pp 57-65 (2010)
Background: Patients with gastric cancer (GC) have a poor survival and biologicals such as Trastuzumab have not been used routinely in these patients. Existing data on HER2 expression and its clinical relevance in GC are still limited and controversi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1c3dd546244ad55cb07c72b3e643d86
https://ora.ox.ac.uk/objects/uuid:7bfe1b69-4071-48f2-8d28-7dea51965e5e
https://ora.ox.ac.uk/objects/uuid:7bfe1b69-4071-48f2-8d28-7dea51965e5e
Autor:
Monserrat Mangas, Flora López, Marc Diez, Juana María Cano, Alberto Carmona-Bayonas, Alfonso Martín Carnicero, Aitziber Gil-Negrete, Manuel Cánovas, Marcelo Garrido, Paula Cerdá, Paola Pimentel, Alicia Hurtado, Marta Martín Richard, Federico Longo, Carolina Hernández Pérez, Ana Montes, Rosario Vidal Tocino, Eva Martínez de Castro, Aranzazu Arias-Martinez, Javier Gallego, Mónica Granja, Laura Visa, Nieves Martinez Lago, Carles Pericay Pijaume, Natalia Castro Unanua, Avinash Ramchandani, Raquel Hernández, Ana Custodio, Tamara Sauri, Paula Jiménez-Fonseca, Gema Aguado, María Luisa Limón, Mariona Calvo, Aitor Azkarate
Publikováno v:
Scientia
Gastric Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Gastric Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Background The purpose of our study was to develop an online calculator to estimate the effect of docetaxel triplets (DPF) in first line of advanced gastric cancer (AGC), and to assess the external validity of docetaxel trials in individual patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82837869875d5aad20b11f5093a89906
https://hdl.handle.net/11351/7737
https://hdl.handle.net/11351/7737
Autor:
Martin J. van den Bent, Katerina Bakunina, Jacoline E C Bromberg, Linda Dirven, Samar Issa, Jeanette K. Doorduijn, Matthijs van der Meulen
Publikováno v:
Journal of Neuro-Oncology, 152(2), 357-362. Kluwer Academic
Journal of Neuro-Oncology, 152(2), 357-362. SPRINGER
Journal of Neuro-Oncology
Journal of Neuro-Oncology, 152(2), 357-362. SPRINGER
Journal of Neuro-Oncology
Introduction To assess the value of the Mini-Mental State Examination (MMSE)-score at baseline in predicting survival in adult primary central nervous system lymphoma (PCNSL) patients. Methods In the HOVON 105/ ALLG NHL 24 phase III study patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a7bd8dbbae5896422024956ad26b38f
https://hdl.handle.net/1887/3251117
https://hdl.handle.net/1887/3251117
Autor:
T. Jeroen N. Hiltermann, Jiacong Wei, Arja ter Elst, Pei Meng, Anthonie J. van der Wekken, Lennart Johansson, Mohamed Z. Alimohamed, Harry J.M. Groen, M. M. Terpstra, Anke van Rijk, Menno Tamminga, Klaas Kok, Rolof P G Gijtenbeek, Anke van den Berg, John W. G. van Putten, Jos A. Stigt, Frank J. G. Scherpen
Publikováno v:
Targeted Oncology
Targeted oncology. SPRINGER
Targeted oncology. SPRINGER
Background The clinical relevance of epidermal growth factor receptor (EGFR) copy number gain in patients with EGFR mutated advanced non-small cell lung cancer on first-line tyrosine kinase inhibitor treatment has not been fully elucidated. Objective